Zaman K, et al. - A 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed to support vaccination programs in developing countries. This study, conducted in Bangladesh, represented an attempt to evaluate immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose vs licensed 1-dose vial presentation in infants. Findings demonstrated the immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative), compared with PHiD-CV 1-dose vial (preservative-free). In addition, researchers noted that for both presentations, immune responses and reactogenicity following primary/booster vaccination were within similar ranges. Notably, PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries.